Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab

REFERENCES

• Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572–584. doi:10.1016/0002-9394(84)90243-5.
   PubMed Web of Science ®Google Scholar
• Amer R, Lois N. Punctate inner choroidopathy. Surv Ophthalmol. 2011;56:36–53. doi:10.1016/j.survophthal.2010.03.009.
   PubMed Web of Science ®Google Scholar
• Perentes Y, Van Tran T, Sickenberg M, Herbort CP. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. OculImmunol Inflamm. 2005;13:219–224. doi:10.1080/09273940490518883.
   PubMed Web of Science ®Google Scholar
• Channa R, Ibrahim M, Sepah Y. et al. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect. 2012;2:113–120. doi:10.1007/s12348-011-0054-6.
   PubMedGoogle Scholar
• Brown J Jr, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal syndrome. Ophthalmology. 1996;103:1100–1105. doi:10.1016/S0161-6420(96)30561-7.
   PubMed Web of Science ®Google Scholar
• Patel KH, Birnbaum AD, Tessler HH, Goldstein DA. Presentation and outcome of patients with punctate inner choroidopathy at a tertiary referral center. Retina. 2011;31:1387–1391. doi:10.1097/IAE.0b013e3182069a8f.
   PubMed Web of Science ®Google Scholar
• Essex RW, Wong J, Fraser-Bell S. et al. Punctate inner choroidopathy: clinical features and outcomes. Arch Ophthalmol. 2010;128:982–987. doi:10.1001/archophthalmol.2010.157.
   PubMedGoogle Scholar
• Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33:1315–1324. doi:10.1097/IAE.0b013e318286cc77.
   PubMed Web of Science ®Google Scholar
• Munk MR1, Jung JJ, Biggee K. et al. Idiopathic multifocal choroiditis/punctate inner choroidopathy with acute photoreceptor loss or dysfunction out of proportion to clinically visible lesions. Retina. 2015;35:334–343. doi:10.1097/IAE.0000000000000370.
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143:977–983. doi:10.1016/j.ajo.2007.02.039.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Mackensen F, Arevalo JF. et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2008;146:410–416. doi:10.1016/j.ajo.2008.05.024.
   PubMed Web of Science ®Google Scholar
• Spiteri Cornish K, Williams GJ, Imrie FR. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol. 2010;21:440–445. doi:10.1016/j.ajo.2008.05.024.
   Web of Science ®Google Scholar
• Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American collaborative retina study group at 24 months. Retina. 2011;31:353–363. doi:10.1097/IAE.0b013e3181ed8cec.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Z, Sun P, Gu F. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Retina. 2012;32:1106–1113. doi:10.1097/IAE.0b013e318242b9da.
   PubMed Web of Science ®Google Scholar
• Peng Y, Zhang X, Mi L, et al. Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy. BMC Ophthalmol. 2017;17:87. doi:10.1186/s12886-017-0481-8.
   PubMed Web of Science ®Google Scholar
• Wu W, Li S, Xu H et al. Treatment of punctate inner choroidopathy with choroidal neovascularization using corticosteroid and intravitreal ranibizumab. Biomed Res web site. https://www.hindawi.com/journals/bmri/2018/1585803. Published September 13, 2018. Accepted August 14, 2018.
   Google Scholar
• Lai TYY, Staurenghi G, Lanzetta P. et al. MINERVA study group. Efficacy and safety of Ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38:1464–1477. doi:10.1097/IAE.0000000000001744.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zuo C, Li M, Chen H, Huang S, Wen F. Spectral-domain optical coherence tomographic findings at each stage of punctate inner choroidopathy. Ophthalmology. 2013 December;120(12):2678–2683. doi:10.1016/j.ophtha.2013.05.012.
   PubMed Web of Science ®Google Scholar
• Niederer RL, Gilbert R, Lightman SL, Tomkins-Netzer O. Risk factors for developing choroidal neovascular membrane and visual loss in punctate inner choroidopathy. Ophthalmology. 2018;125:288–294. doi:10.1016/j.ophtha.2017.09.002.
   PubMed Web of Science ®Google Scholar
• Querques G, Tran TH, Forte R, Querques L, Bandello F, Souied EH. Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol. 2012;250:479–484. doi:10.1007/s00417-011-1831-5.
   PubMed Web of Science ®Google Scholar
• Querques G, Srour M, Massamba N. et al. Functional characterization and multimodal imaging of treatment-naive “quiescent” choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:6886–6892. doi:10.1167/iovs.13-11665.
   PubMed Web of Science ®Google Scholar